D-1545-2020 Class II Terminated

Recalled by Hetero Labs Limited (Unit V) — Badepalle, N/A

FDA drug recall D-1545-2020 was initiated by Hetero Labs Limited (Unit V) on Aug 6, 2020 and is designated Class II. Reason for recall: Failed Tablet/Capsule Specification; complaint of bulging tablet The recall status is terminated (terminated Jan 24, 2022). Affected quantity: 43,512 bottles.

Recall details

Product Type
Drugs
Report Date
Sep 2, 2020
Initiation Date
Aug 6, 2020
Termination Date
Jan 24, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
43,512 bottles

Product description

Losartan Potassium Tablets USP, 50 mg, 90 count bottles, Rx only, Manufactured for: Camber Pharmaceuticals, Inc., Piscataway, NJ by Hetero Labs, Limited, Mahabubragar, India

Reason for recall

Failed Tablet/Capsule Specification; complaint of bulging tablet

Distribution pattern

Product was distributed to major wholesalers/distributors throughout the United States.

Code information

Batch # LOA19357A, exp. date 09/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1545-2020
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1545-2020. Report a data issue: hello@regdatalab.com.